Trader consensus implies a 73% probability that the CDC will issue a Level 3 Travel Health Notice—recommending travelers reconsider nonessential trips due to an outbreak posing substantial risk—by December 31, 2026, driven by escalating U.S. measles outbreaks with 1,792 confirmed cases and 22 outbreaks as of mid-April, primarily among unvaccinated individuals amid declining immunization rates. Compounding this, H5N1 bird flu persists with 71 U.S. human cases since 2024 (mostly occupational exposures, two deaths, no person-to-person transmission per CDC surveillance), alongside global polio prompting a March Level 2 advisory for 30+ countries. While public health risk remains low, these trajectories signal potential for intensified CDC response; weekly FluView reports and state-level case updates will provide key catalysts.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedCDC issues Level 3 warning by December 31?
CDC issues Level 3 warning by December 31?
$115,462 Vol.
$115,462 Vol.
$115,462 Vol.
$115,462 Vol.
A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Market Opened: Jan 19, 2026, 3:15 PM ET
Resolver
0x65070BE91...A Level 3 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Trader consensus implies a 73% probability that the CDC will issue a Level 3 Travel Health Notice—recommending travelers reconsider nonessential trips due to an outbreak posing substantial risk—by December 31, 2026, driven by escalating U.S. measles outbreaks with 1,792 confirmed cases and 22 outbreaks as of mid-April, primarily among unvaccinated individuals amid declining immunization rates. Compounding this, H5N1 bird flu persists with 71 U.S. human cases since 2024 (mostly occupational exposures, two deaths, no person-to-person transmission per CDC surveillance), alongside global polio prompting a March Level 2 advisory for 30+ countries. While public health risk remains low, these trajectories signal potential for intensified CDC response; weekly FluView reports and state-level case updates will provide key catalysts.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions